Working with mice, hamsters, and nonhuman primates, Penn researchers found that a modified version of the mRNA COVID-19 ...

Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...

MacMaster, Ph.D., associate professor of Microbiology-Immunology, have discovered that administering an antibody treatment ...

The UK is making progress in developing cancer vaccines, but there are still challenges ahead, Chris Baraniuk reports The UK is on its way to becoming a hotbed of cancer vaccine trials. In May this ...

mRNA technology was used to develop Moderna’s Covid-19 jab and is also being trialled to make personalised cancer vaccines as ...

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global ...

cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. Read More on MRNA: Moderna NewsMORE Related ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

Working with animals, Penn researchers modified the mRNA vaccine to target C. difficile, an infection that kills 30,000 in ...

the mRNA vaccine is an established platform, which Penn researchers are using to also target Lyme disease, norovirus, and a herpes virus, and are working on other targets such as cancer.